Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-02-17
1997-03-25
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546121, A61K 3144, C07D47104
Patent
active
056145314
ABSTRACT:
Compounds of the formula I ##STR1## and the corresponding 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives, their physiologically acceptable salts and/or solvates, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporosis, oncoses, stroke, myocardial infarct, inflammations, arteriosclerosis and osteolytic disorders.
REFERENCES:
patent: 4767755 (1988-08-01), George et al.
patent: 4808594 (1989-02-01), George et al.
patent: 4891371 (1990-01-01), George et al.
patent: 4990506 (1991-02-01), George et al.
patent: 5084466 (1992-01-01), Alig et al.
patent: 5256812 (1993-10-01), Alig et al.
patent: 5399585 (1995-03-01), Alig et al.
patent: 5434150 (1995-07-01), Austel
Ruoslaliti E, Pierschbachen MD (1987) Science 238, 491.
Bernotat-Danielowski Sabine
Gante Joachim
Juraszyk Horst
Melzer Guido
Wurziger Hanns
Huang Evelyn
Ivy C. Warren
Merck Patent Gesellschaft mit beschrankter Haftung
LandOfFree
Adhesion receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adhesion receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adhesion receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2203672